Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

490 recalls · Class II, newest first

Class II · Moderate risk

BD ChloraPrep Clear

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel

Ongoing Sterility / contamination CareFusion 213, LLC NDC 54365-400-32 D-0645-2026
Class II · Moderate risk

BD PurPrep

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel

Ongoing Sterility / contamination CareFusion 213, LLC NDC 54365-014-42 D-0644-2026
Class II · Moderate risk

BD ChloraPrep Hi-Lite Orange

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel

Ongoing Sterility / contamination CareFusion 213, LLC NDC 54365-400-35 D-0643-2026
Class II · Moderate risk

Gemcitabine Injection

Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.

Ongoing Temperature excursion McKesson D-0714-2026
Class II · Moderate risk

Imuldosa

Lack of assurance of Sterility:

Ongoing Sterility / contamination Accord Biopharma INC NDC 69448-019-26 D-0653-2026
Class II · Moderate risk

Lacosamide Tablets

Presence of a Foreign Tablets: Complaint received, possible mix-up of Selexipag 1000 mcg tablet in a bottle of Lacosamide Tablets USP, 100mg.

Ongoing Particulate / foreign matter Annora Pharma Private Limited NDC 31722-813-60 D-0626-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0642-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0641-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0640-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0639-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0638-2026

Recalls by year